[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.180.70. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
February 3, 1999

Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim Co-EditorIndividualAuthor

JAMA. 1999;281(5):414-419. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203

To the Editor: The results of AFCAPS/TexCAPS1 suggest that HMG-CoA reductase inhibitors are effective at primary prevention in low-risk patients. The accompanying Commentary points out that the 25% to 40% risk reduction in patients whose main risk factor was a low HDL-C level came at considerable cost, more than $1000 per year in drug costs alone.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×